Canine Atopic Dermatitis: Veterinary Biologic in Development for Canine Atopy
Breakthrough technology under development for dogs with atopic dermatitis - an IMULAN Program
Canine Atopic Dermatitis - IMULAN is developing a revolutionary patented immuno-therapy (veterinary biologic) for dogs with atopic dermatitis, skin allergies, and skin infections. TRIAL has started as of OCT 2012!
Contact: IMULAN BioTherapeutics, LLC: www.IMULAN.com; info@imulan.com
Atopic Dermatitis in Dogs
It is estimated that atopic dermatitis affects up to 7% of the dogs in the United States, or over 5 million dogs. Atopic dermatitis is also known as atopy or allergic dermatitis (skin allergies). Atopic dermatitis in dogs can be categorized into seasonal and non-seasonal atopy. Dogs are often referred to veterinary dermatologists for diagnostics and treatments for atopy.
Dogs with atopy may get desensitization therapy, cyclosporine, tacrolimus, steroids, shampoos, and other products as atopic dermatitis treatments. Regardless, many dogs remain uncomfortable despite these treatments. That is why we are developing a brand new, first-in-class approach targeting atopic dermatitis at its source.
Cause of Atopy in Dogs
Canine atopy is triggered by allergens (antigens) which can cause immune cells to react and produce imunoglobulin E (IgE). IgE triggers skin allergies and further irritation and itching (pruritis). The central regulator of the IgE response is the T-helper (Th) cell, further categorized as Th1, Th2 and Th17 cells. It is the Th2 cells that produce signals which amplify the production of IgE.
IMULAN has targeted the T-helper cell using an optimized T-cell Receptor (TCR) peptide technology. IMULAN's TCR peptide engages the T-helper cell receptor and have been shown to restore normal immune function (Th1/Th2 balance). Previous studies in dogs and cats have demonstrated significant improvement in atopic dermatitis and stomatitis respectively.
Our Clinical Trial Sites
IMULAN's new TCR technology is undergoing studies to obtain approval as a treatment for atopic dermatitis in dogs. Pet owners may located our trial sites by going to our clinical trial site webpage. IMULAN is studying this new atopic dermatitis treatment with board certified veterinary dermatologists and research groups. Our dog atopy treatment trial is monitored by veterinary research scientists.
If you are a veterinarian interested in participating in our treatment for atopic dermatitis, please contact us at info@imulan.com or use the contact form on the Study Info page.
IMULAN's Atopy Treatment
IMULAN's new T-Cell Receptor (TCR) peptide therapy is a breakthrough advance in modulating the underlying cause of canine atopy. T-Cell Receptor Peptides are small peptides that directly target the T-helper cell. These are considered immunomodulatory and classified in veterinary medicine as immunobiologics. Proposed key advantages of IMULAN's treatment for dogs with atopic dermatitis include SQ administration, long duration of effect (>3 months), targets the underlying cause, and is cost effective. Preliminary double blind studies have already demonstrated a highly significant effect in dogs with severe, refractory atopic dermatitis.
Dog Atopic Dermatitis Trial Starts
November 1, 2012: IMULAN BioTherapeutics, LLC has officially commenced with their study in dogs with atopic dermatitis. On October 15th, 2012, the United States Department of Agriculture (USDA) gave authorization […]